Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Hisamitsu Pharmaceutical Co ( (JP:4530) ).
Hisamitsu Pharmaceutical Co. reported a decline in its financial performance for the first quarter of the fiscal year ending February 28, 2026, with net sales decreasing by 3.2% and profit attributable to owners of the parent dropping by 46.4% year-on-year. Despite the downturn, the company forecasts a full-year increase in net sales and operating profit by 5.8%, and plans to increase its annual dividend, including a commemorative dividend for the 30th anniversary of MOHRUS® Tapes.
More about Hisamitsu Pharmaceutical Co
Hisamitsu Pharmaceutical Co., Inc. is a Japanese company listed on the Tokyo, Nagoya, and Fukuoka stock exchanges. The company specializes in the pharmaceutical industry, primarily known for its transdermal therapeutic products such as SALONPAS® and MOHRUS® Tapes, focusing on pain relief and other therapeutic applications.
Average Trading Volume: 154,357
Technical Sentiment Signal: Sell
Current Market Cap: Yen292.2B
Learn more about 4530 stock on TipRanks’ Stock Analysis page.